Mind Medicine Sees FDA Place Clinical Hold On Phase 2b Study

Mind Medicine (NEO: MMED) this morning indicated that things are not going quite to plan with an IND submission for a Phase 2b trial focused on examining the use of LSD for the treatment of generalized anxiety disorder. The FDA evidently has placed a clinical hold on the study.

The justification for the clinical hold has not yet been revealed, with the company commenting that it expects additional details from the decision within the next thirty days. A clinical hold, as described by the FDA, is “an order issued by FDA to the sponsor of an IND application to delay a proposed clinical investigation or to suspend an ongoing investigation.”

A number of justifications exist for why a clinical hold may take place, but the short of it is that the regulator is not happy with one aspect of the proposed study. While the first phase outlines five potential reasons for why a study may be placed on hold, including unreasonable risk for human subjects, unqualified investigators, insufficient information, risk of reproductive or developmental toxicity and an erroneous brochure, the second phase sees the addition of potential hold due to deficient study design to meet stated objectives. It is currently unclear what grounds the study was placed on hold for.

Cambria Gold Mines — sponsored Sponsored · Cambria Gold Mines

Further information was not provided by the company on the matter.

Mind Medicine last traded at $2.12 on the Neo.


Information for this briefing was found via Sedar and MindMed. The author has no securities or affiliations related to this organization. Not a recommendation to buy or sell. Always do additional research and consult a professional before purchasing a security. The author holds no licenses.

Video Articles

Is Agnico Eagle Seabridge Gold’s Mystery Lender?

This Gold Giant Is Building 1.5 Million More Ounces a Year | Agnico Eagle Q3 Earnings

This Gold Giant Was a Mess. Now It’s Back! | Barrick Mining Q3 2026 Earnings

Recommended

Epic Gold Delivers Maiden 279,000 Ounce Inferred Resource at Wilson Project

First Phosphate Adds UK Export Finance to Growing Export Credit Lineup With C$220 Million Letter of Interest

Related News

Mind Medicine Sees CEO Sell $24.7 Million In Company Stock

It appears that uplisting to the Nasdaq is good for business. Or, at least for...

Wednesday, May 26, 2021, 10:14:37 AM

Mind Medicine Completes Pre-IND Meeting For LSD Assisted Therapy In Anxiety

Mind Medicine (NEO: MMED) this morning issued a brief update related two products within its...

Monday, December 14, 2020, 07:54:19 AM

MindMed Launches R(-)-MDMA Program For Autism Spectrum Disorder Symptoms

Mind Medicine Inc. (NEO: MMED), more commonly known as MindMed, recently launched a program to...

Tuesday, October 26, 2021, 10:35:00 AM

MindMed Activist Investor Moves To Take Control Of Board

MindMed (NASDAQ: MNMD) has seen its activist investor file a preliminary proxy statement for its...

Friday, April 21, 2023, 09:41:30 AM

Mind Medicine Raises $92.1 Million Via Bought Deal Financing

Mind Medicine (NEO: MMED) has closed its previously announced bought deal financing, raising nearly double...

Thursday, January 7, 2021, 09:31:54 AM